Apport de l'iode 131 dans la prise en charge des cancers differencies de la thyroide [d'origine vesiculaire]

Radioiodine 131 has an important place in the management of well differentiated thyroid cancer. Patient preparation for radioiodine 131 administration must be rigorous and is based on the stimulation of endogenous TSH production, which requires a hypothyroid state after withdrawal of suppressive T4-therapy. The introduction of recombinant human TSH would simplify the protocol of preparation and improve the quality of life of patients. The diagnosis place of radioiodine 131 knew significant changes following the introduction of the serum thyroglobulin measurement. This tumour marker has a central role in the strategy of follow up and tends to be the principal element of indication for a diagnosis exploration with radioidine 131. the systematic ablation of thyroid remnants remains controversial particularly in patients with good prognosis fectors; the efficacy of low activities is also still debatable. The optimal follow up strategy and the indication of remnant ablation must take in account the prognosis factors of survival and recurrence. Radioiodine-131 therapy permits frequently the cure of distant metastases, particularly in infraradiological pulmonary forms. This fact outines the importance of an early detection of tumour recurrence based on the conjunction of radioiodine 131 and thyroglobulin. Side effects of radioiodine 131 therapy are generally limited it the precautionary measures are well applied; leukaemia constitutes the main risk but this complication is very uncommon and occurs after a high cumulative activity